Interaction check not available yet — this product's ingredients haven't been matched to our database.
Dietary supplement

Ther-Biotic for Infants Ingredients & Drug Interactions

by Klaire Labs

Powder Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Ther-Biotic for Infants is a dietary supplement by Klaire Labs with 2 active ingredients.Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Ther-Biotic for Infants by Klaire Labs

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 10 active ingredients.
  • “Proprietary Probiotic Blend” is a proprietary blend — the label gives one combined amount (500 mg) without saying how much of each component you get.
  • “Lactobacillus species” is listed as a grouped ingredient — the label gives one combined amount (150 mg) without saying how much of each component you get.
  • “Bifidobacterium species” is listed as a grouped ingredient — the label gives one combined amount (350 mg) without saying how much of each component you get.

Ther-Biotic for Infants is a powder formula with 10 active ingredients, all of them live probiotic bacteria — species of Bifidobacterium and Lactobacillus — chosen to support infant gut health. These are "good" bacteria meant to help balance the natural flora in your baby's digestive tract.

The product contains no inactive ingredients or fillers.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Infant digestive health and gut microbiome support.
  • We looked for evidence on: Antibiotic-associated diarrhea, Colic, Constipation, Diarrhea, Irritable bowel syndrome (IBS), Necrotizing enterocolitis (NEC) — and 4 related terms.
  • The strongest evidence on file: Bifidobacterium Bifidum is rated "Possibly Effective" for Irritable bowel syndrome (IBS) (Natural Medicines).
  • Also on file: Bifidobacterium Breve is rated "Insufficient Reliable Evidence To Rate" for Antibiotic-associated diarrhea, Constipation, Rotaviral diarrhea, Irritable bowel syndrome (IBS), and more.

The effectiveness of individual bacteria in this formula varies. Bifidobacterium bifidum shows possibly effective evidence for irritable bowel syndrome and respiratory tract infections.

For most of the other conditions the ingredient data covers — including allergic rhinitis, antibiotic-associated diarrhea, anxiety, asthma, and cognitive decline — the evidence we hold is insufficient to rate whether these bacteria work. Your pediatrician can help you decide whether this product is right for your infant's particular situation.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 4 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 4 of 4.
  • General safety write-ups exist for 4 of 4.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

The probiotic bacteria in this formula are generally well tolerated in healthy infants, but caution is advised for babies who are very ill or have weakened immune systems — talk with your pediatrician before use if that applies. Rare but serious cases of bacterial bloodstream infection (bacteremia) related to Bifidobacterium species have been reported in critically ill or preterm infants using probiotics; in one reviewed study of hospitalized preterm and term infants given Bifidobacterium breve, bacteremia occurred in 2% of patients.

Milder side effects such as bloating, flatulence, abdominal discomfort, or constipation have been reported rarely with probiotic use. Safety data are limited, so use this product only under your doctor's guidance.

Bifidobacterium longum is rated possibly safe in pregnancy and lactation; data for the other bacteria in this formula are either insufficient or not on file.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 4 of the 4 matched ingredients can interact with medications — Bifidobacterium Breve, Bifidobacterium Bifidum, Bifidobacterium Longum, Lactobacillus Gasseri.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

The main medication concern is antibiotic drugs. If your infant is taking any antibiotic, separate doses of this probiotic from the antibiotic — your pediatrician or pharmacist can advise on the best timing to preserve the probiotic's benefit.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Ther-Biotic for Infants is a multi-strain probiotic powder designed for infants' digestive health. It's generally well tolerated in healthy babies but warrants caution in very ill or immunocompromised infants, and it interacts with antibiotics by potentially reducing probiotic effectiveness if dosed together.

Talk with your pediatrician before starting this product, especially if your baby is on or about to receive antibiotics or has any underlying illness.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 4 of 10 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 23, 2023.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Ther-Biotic for Infants, straight from the product label.

Brand Klaire Labs
Barcode (UPC) 709616012239
Net contents 2.33 Ounce(s); 66 Gram(s)
Market status On market
Date entered into DSLD Jan 23, 2023
DSLD ID 281258
Product type Non-nutrient/non-botanical
Supplement form Powder
Dietary claims / uses All Other
Intended target group(s) Children (All), Infants/Baby (0 - 1 Year), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Ther-Biotic for Infants by Klaire Labs, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Infants
Minimum serving Sizes:
0.5 Gram(s), 0.5 Gram(s)
Maximum serving Sizes:
0.5 Gram(s), 0.5 Gram(s)
Servings per container
120
UPC/BARCODE
709616012239
IngredientAmount% DV
Bifidobacterium infantis0 NP--
Lactobacillus paracasei0 NP--
Bifidobacterium breve0 NP--
Bifidobacterium animalis lactis0 NP--
Bifidobacterium longum0 NP--
Bifidobacterium bifidum0 NP--
Lactobacillus casei0 NP--
Lactobacillus salivarius0 NP--
Proprietary Probiotic Blend500 mg--
Lactobacillus rhamnosus0 NP--
Lactobacillus gasseri0 NP--
Lactobacillus species150 mg--
Bifidobacterium species350 mg--

Other ingredients: None

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Precautions

Caution: Do not feed powder directly to infants or children. If the infant or child has a medical condition, taking prescription drugs, or under the age of 6 months, consult your physixian before using this product. Keep out of reach of children.

Do not use if shrinkwrap is broken or missing.

Formulation

Free of the following common allergens: Milk/casein, eggs, fish, shellfish, tree nuts, peanuts, wheat, gluten, and soybeans. Contains no artificial colors, flavors, or preservatives.

Produced under a strict quality management system in compliance with Good Manufacturing Practices (GMPs) and third-party quality certifications.

Multispecies

Suggested/Recommended/Usage/Directions

Suggested Use: For children over 12 months: 1 scoop, once or twice daily. For infants 6 to 12 months: 1 scoop daily. Mix product in infant formula, milk, juice, or sprinkled on food such as yogurt, apple sauce or cereal or as recommended by your healthcare professional. For breast-feeding mothers, product can be added to expressed milk, or small amounts at a time can be dispensed by placing on nipple or finger.

Storage

Keep refrigerated.

Formula

5 billion CFU

Brand IP Statement(s)

SFI

See for yourself

Ther-Biotic for Infants by Klaire Labs label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Ther-Biotic for Infants by Klaire Labs

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size0.5 Gram(s) Dosage formPowder Servings per container120 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Probiotic Blend

500 mg per serving
  • › Lactobacillus species
  • › Bifidobacterium species

Other (inactive) ingredients: None. These complete the product’s ingredient list but are not active constituents.

Interaction report

Ther-Biotic for Infants by Klaire Labs Drug Interactions

Want to check YOUR meds against Ther-Biotic for Infants?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Ther-Biotic for Infants with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

The maker

Brand information

Manufacturer and brand details for Ther-Biotic for Infants, from the product label.

Klaire Labs

See all Klaire Labs products
Name
SFI USA
City
Reno
State
NV
ZipCode
89521
Web Address
Klaire.com
Pharmacist Counseling Corner

Ther-Biotic for Infants by Klaire Labs: Common Questions

Does Ther-Biotic for Infants by Klaire Labs interact with any medications?
Yes. Based on its ingredients, Ther-Biotic for Infants has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Ther-Biotic for Infants contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I give this to my newborn if she's on antibiotics?
The live bacteria in this powder may be killed if given at the same time as antibiotics, making the probiotic less effective. Talk with your pediatrician about separating the doses — typically taking them a few hours apart can help. If your baby is critically ill or very premature, your doctor may want to discuss this product more carefully before use.
What are the active ingredients in this formula?
It's a blend of 10 live probiotic bacteria species, including several Bifidobacterium strains (infantis, breve, animalis lactis, longum, and bifidum) and several Lactobacillus strains (paracasei, casei, salivarius, rhamnosus, and gasseri). Each is meant to support healthy gut bacteria balance.
What side effects might my baby experience?
Most infants tolerate this well, but bloating, gas, abdominal discomfort, and constipation have been reported rarely. Very rarely, serious infections (bacteremia) have occurred in critically ill or premature infants using Bifidobacterium probiotics — this is why it's important to check with your pediatrician before use, especially if your baby is in the hospital or has any immune concerns.
Is this safe during breastfeeding?
Bifidobacterium longum, one ingredient in this formula, is rated possibly safe during lactation. Safety data for the other bacteria are either limited or not on file, so check with your pediatrician or lactation consultant before use.
Does this product have any fillers or other inactive ingredients?
No — this formula contains only the active probiotic bacteria and no fillers or other inactive ingredients.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Ther-Biotic for Infants is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Ther-Biotic for Infants label
Sources

Sources & How We Checked

Ther-Biotic for Infants's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 49 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Lactobacillus Gasseri 12 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Ramachandran L, Dontaraju VS, Patel K. Lactobacillus-associated spontaneous bacterial peritonitis in a liver cirrhosis patient on probiotics. Cureus. 2020;12(12):e11896. PubMed
  3. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  4. Ranchal P, Gupta R, Goldberg R, A Lobo S, Pascual A, El Khoury MY. Penicillin-sensitive Lactobacillus jensenii bacteremia. Am J Ther 2021;28(2):e250-e252. PubMed
  5. Grazioli-Gauthier L, Rigamonti E, Leo LA, Martinetti Lucchini G, Lo Priore E, Bernasconi E. Lactobacillus jensenii mitral valve endocarditis: Case report, literature review and new perspectives. IDCases 2022;27:e01401. PubMed
  6. Toprak NU, Bozan T, Yilmaz S, Buyukbayrak EE, Tigen ET. Polymicrobial bacteremia due to Lactobacillus jensenii and Veillonella montpellierensis in a pregnant patient; case report and review of literature. Anaerobe 2022;75:102576. PubMed
  7. Chazan B, Raz R, Shental Y, Sprecher H, Colodner R. Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis. Isr Med Assoc J 2008;10(2):164-5.
  8. Ramos-Coria D, Canto-Losa J, Carrillo-Vázquez D, Carbajal-Morelos L, Estrada-León R, Corona-Rodarte E. Lactobacillus gasseri liver abscess and bacteremia: a case report. BMC Infect Dis 2021;21(1):518. PubMed
  9. Elikowski W, Malek-Elikowska M, Lisiecka M, Bodora A, Wisniewska K, Oko-Sarnowska Z. Lactobacillus gasseri endocarditis on the aortic valve bioprosthesis - a case report. Pol Merkur Lekarski 2017;43(257):220-223.
  10. Esquibel A, Dababneh AS, Palraj BR. Lactobacillus gasseri causing bilateral empyema. Case Rep Infect Dis 2017;2017:4895619.
  11. Tleyjeh IM, Routh J, Qutub MO, Lischer G, Liang KV, Baddour LM. Lactobacillus gasseri causing Fournier's gangrene. Scand J Infect Dis 2004;36(6-7):501-3. PubMed
  12. Dickgiesser U, Weiss N, Fritsche D. Lactobacillus gasseri as the cause of septic urinary infection. Infection 1984;12(1):14-6. PubMed

See these in context on the Lactobacillus Gasseri monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring